165 related articles for article (PubMed ID: 33264302)
1. Refinement of the CS6-expressing enterotoxigenic Escherichia coli strain B7A human challenge model: A randomized trial.
Talaat KR; Porter CK; Jaep KM; Duplessis CA; Gutierrez RL; Maciel M; Adjoodani B; Feijoo B; Chakraborty S; Brubaker J; Trop SA; Riddle MS; Joseph SS; Bourgeois AL; Prouty MG
PLoS One; 2020; 15(12):e0239888. PubMed ID: 33264302
[TBL] [Abstract][Full Text] [Related]
2. Oral delivery of Hyperimmune bovine serum antibodies against CS6-expressing enterotoxigenic
Talaat KR; Porter CK; Bourgeois AL; Lee TK; Duplessis CA; Maciel M; Gutierrez RL; DeNearing B; Adjoodani B; Adkinson R; Testa KJ; Feijoo B; Alcala AN; Brubaker J; Beselman A; Chakraborty S; Sack D; Halpern J; Trop S; Wu H; Jiao J; Sullivan E; Riddle MS; Joseph SS; Poole ST; Prouty MG
Gut Microbes; 2020 Nov; 12(1):1732852. PubMed ID: 32167011
[TBL] [Abstract][Full Text] [Related]
3. Pathogenicity and immune response measured in mice following intranasal challenge with enterotoxigenic Escherichia coli strains H10407 and B7A.
Byrd W; Mog SR; Cassels FJ
Infect Immun; 2003 Jan; 71(1):13-21. PubMed ID: 12496144
[TBL] [Abstract][Full Text] [Related]
4. Refinement of a human challenge model for evaluation of enterotoxigenic Escherichia coli vaccines.
Harro C; Chakraborty S; Feller A; DeNearing B; Cage A; Ram M; Lundgren A; Svennerholm AM; Bourgeois AL; Walker RI; Sack DA
Clin Vaccine Immunol; 2011 Oct; 18(10):1719-27. PubMed ID: 21852546
[TBL] [Abstract][Full Text] [Related]
5. Characterization of Mucosal Immune Responses to Enterotoxigenic Escherichia coli Vaccine Antigens in a Human Challenge Model: Response Profiles after Primary Infection and Homologous Rechallenge with Strain H10407.
Chakraborty S; Harro C; DeNearing B; Ram M; Feller A; Cage A; Bauers N; Bourgeois AL; Walker R; Sack DA
Clin Vaccine Immunol; 2016 Jan; 23(1):55-64. PubMed ID: 26581889
[TBL] [Abstract][Full Text] [Related]
6. Attenuated Escherichia coli strains expressing the colonization factor antigen I (CFA/I) and a detoxified heat-labile enterotoxin (LThK63) enhance clearance of ETEC from the lungs of mice and protect mice from intestinal ETEC colonization and LT-induced fluid accumulation.
Byrd W; Boedeker EC
Vet Immunol Immunopathol; 2013 Mar; 152(1-2):57-67. PubMed ID: 23122616
[TBL] [Abstract][Full Text] [Related]
7. Hyperimmune Bovine Colostral Anti-CS17 Antibodies Protect Against Enterotoxigenic Escherichia coli Diarrhea in a Randomized, Doubled-Blind, Placebo-Controlled Human Infection Model.
Savarino SJ; McKenzie R; Tribble DR; Porter CK; O'Dowd A; Sincock SA; Poole ST; DeNearing B; Woods CM; Kim H; Grahek SL; Brinkley C; Crabb JH; Bourgeois AL
J Infect Dis; 2019 Jul; 220(3):505-513. PubMed ID: 30897198
[TBL] [Abstract][Full Text] [Related]
8. Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administered alone and together with dmLT adjuvant.
Holmgren J; Bourgeois L; Carlin N; Clements J; Gustafsson B; Lundgren A; Nygren E; Tobias J; Walker R; Svennerholm AM
Vaccine; 2013 May; 31(20):2457-64. PubMed ID: 23541621
[TBL] [Abstract][Full Text] [Related]
9. Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study.
McKenzie R; Bourgeois AL; Frech SA; Flyer DC; Bloom A; Kazempour K; Glenn GM
Vaccine; 2007 May; 25(18):3684-91. PubMed ID: 17313998
[TBL] [Abstract][Full Text] [Related]
10. A Phase 1 dose escalating study of double mutant heat-labile toxin LTR192G/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by sublingual or oral immunization.
Bernstein DI; Pasetti MF; Brady R; Buskirk AD; Wahid R; Dickey M; Cohen M; Baughman H; El-Khorazaty J; Maier N; Sztein MB; Baqar S; Bourgeois AL
Vaccine; 2019 Jan; 37(4):602-611. PubMed ID: 30563789
[TBL] [Abstract][Full Text] [Related]
11. A tripartite fusion, FaeG-FedF-LT(192)A2:B, of enterotoxigenic Escherichia coli (ETEC) elicits antibodies that neutralize cholera toxin, inhibit adherence of K88 (F4) and F18 fimbriae, and protect pigs against K88ac/heat-labile toxin infection.
Ruan X; Liu M; Casey TA; Zhang W
Clin Vaccine Immunol; 2011 Oct; 18(10):1593-9. PubMed ID: 21813665
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the immunogenicity and protective efficacy of a recombinant CS6-based ETEC vaccine in an Aotus nancymaae CS6 + ETEC challenge model.
Ramakrishnan A; Joseph SS; Reynolds ND; Poncet D; Maciel M; Nunez G; Espinoza N; Nieto M; Castillo R; Royal JM; Poole S; McVeigh A; Rollenhagen JE; Heinrichs J; Prouty MG; Simons MP; Renauld-Mongénie G; Savarino SJ
Vaccine; 2021 Jan; 39(3):487-494. PubMed ID: 33357957
[TBL] [Abstract][Full Text] [Related]
13. Immune response, ciprofloxacin activity, and gender differences after human experimental challenge by two strains of enterotoxigenic Escherichia coli.
Coster TS; Wolf MK; Hall ER; Cassels FJ; Taylor DN; Liu CT; Trespalacios FC; DeLorimier A; Angleberger DR; McQueen CE
Infect Immun; 2007 Jan; 75(1):252-9. PubMed ID: 17074855
[TBL] [Abstract][Full Text] [Related]
14. Impact of lower challenge doses of enterotoxigenic Escherichia coli on clinical outcome, intestinal colonization and immune responses in adult volunteers.
Chakraborty S; Harro C; DeNearing B; Brubaker J; Connor S; Maier N; Dally L; Flores J; Bourgeois AL; Walker R; Sack DA
PLoS Negl Trop Dis; 2018 Apr; 12(4):e0006442. PubMed ID: 29702652
[TBL] [Abstract][Full Text] [Related]
15. Enterotoxigenic Escherichia coli Adhesin-Toxoid Multiepitope Fusion Antigen CFA/I/II/IV-3xSTa
Nandre R; Ruan X; Lu T; Duan Q; Sack D; Zhang W
Infect Immun; 2018 Mar; 86(3):. PubMed ID: 29263112
[TBL] [Abstract][Full Text] [Related]
16. Randomized clinical trial assessing the safety and immunogenicity of oral microencapsulated enterotoxigenic Escherichia coli surface antigen 6 with or without heat-labile enterotoxin with mutation R192G.
Lapa JA; Sincock SA; Ananthakrishnan M; Porter CK; Cassels FJ; Brinkley C; Hall ER; van Hamont J; Gramling JD; Carpenter CM; Baqar S; Tribble DR
Clin Vaccine Immunol; 2008 Aug; 15(8):1222-8. PubMed ID: 18579693
[TBL] [Abstract][Full Text] [Related]
17. Review on pathogenicity mechanism of enterotoxigenic Escherichia coli and vaccines against it.
Mirhoseini A; Amani J; Nazarian S
Microb Pathog; 2018 Apr; 117():162-169. PubMed ID: 29474827
[TBL] [Abstract][Full Text] [Related]
18. Antigen-specific memory B-cell responses to enterotoxigenic Escherichia coli infection in Bangladeshi adults.
Alam MM; Aktar A; Afrin S; Rahman MA; Aktar S; Uddin T; Rahman MA; Al Mahbuba D; Chowdhury F; Khan AI; Bhuiyan TR; Begum YA; Ryan ET; Calderwood SB; Svennerholm AM; Qadri F
PLoS Negl Trop Dis; 2014 Apr; 8(4):e2822. PubMed ID: 24762744
[TBL] [Abstract][Full Text] [Related]
19. Current Progress in Developing Subunit Vaccines against Enterotoxigenic Escherichia coli-Associated Diarrhea.
Zhang W; Sack DA
Clin Vaccine Immunol; 2015 Sep; 22(9):983-91. PubMed ID: 26135975
[TBL] [Abstract][Full Text] [Related]
20. Passive antibodies derived from intramuscularly immunized toxoid fusion 3xSTa
Nandre RM; Duan Q; Wang Y; Zhang W
Vaccine; 2017 Jan; 35(4):552-556. PubMed ID: 28017433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
